comprehensive -WSS

comprehensive

author：fashion 2025-09-28 01:34:56 - browse：1

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： The (many) problems with a new study criticizing cancer screening

focus

WSS

Think you might have Covid

Research misconduct: Proposed new rules face resistance

Why doctors need education on FDA device approval process

Snackable artificial intelligence, expert AI, and the pharma industry

Snackable artificial intelligence, expert AI, and the pharma industry

The (many) problems with a new study criticizing cancer screening

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Anesthesiologist group: stop taking Ozempic before surgery

eGenesis tests gene

BioMarin wins approval for gene therapy to treat hemophilia A

Prior authorization will have to move faster under new Biden rule

Wildfire smoke exposes gaps in outdoor worker protections

A rare thyroid diagnosis led to unexpected, all

Novavax promises a turnaround & Lilly roils the obesity market

Biotech venture capitalists face new demands from investors

What does generative AI mean for health care? We asked experts

Covid hospitalizations on the rise, Humana says

hotspot

Readout Newsletter: Merck, J&J, and long Covid

Research misconduct: Proposed new rules face resistance

Parkinson’s finding may lead to tests and, someday, treatments

The (many) problems with a new study criticizing cancer screening

A new House health package & hospitals’ new site

Why Novartis is changing the name of its research labs

explore

hotspot

focus

knowledge